# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -BERKELEY HEIGH...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study i...